Myles Minter, an analyst from William Blair, has initiated a new Buy rating on Dianthus Therapeutics (DNTH).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Myles Minter has given his Buy rating due to a combination of factors that highlight the potential of Dianthus Therapeutics in the competitive autoimmune complement inhibitor market. The company is advancing DNTH103, a promising monoclonal antibody targeting C1s, which is currently in clinical trials for autoimmune neuromuscular conditions. The anticipated data from the Phase II MaGic trial in generalized myasthenia gravis (gMG) and the Phase II/III CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy (CIDP) are expected to be significant catalysts for the stock, with the former expected in September 2025 and the latter in the second half of 2026.
Furthermore, the competitive landscape, dominated by products like Soliris and Ultomiris, presents a lucrative opportunity for DNTH103, especially given its potential efficacy and safety advantages. The company’s strong cash position, which extends its financial runway into the second half of 2027, supports its ongoing clinical endeavors. Additionally, the potential for mergers and acquisitions adds another layer of attractiveness to the stock, contingent on positive clinical outcomes. These factors collectively underpin Minter’s optimistic outlook and Buy rating on Dianthus Therapeutics.
According to TipRanks, Minter is a 4-star analyst with an average return of 8.1% and a 46.01% success rate. Minter covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Moderna, and Arcturus Therapeutics.
In another report released on June 30, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target.